Search
SGS518
go.drugbank.com/drugs/DB05042ExperimentalSGS518, a novel antagonist for the 5HT6 subtype of the serotonin receptor, is being developed as a treatment for Cognitive Impairment Associated with Schizophrenia (CIAS).
(R)-acetoin
go.drugbank.com/drugs/DB04364ExperimentalA product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
(S)-acetoin
go.drugbank.com/drugs/DB02788ExperimentalA product of fermentation. It is a component of the butanediol cycle in microorganisms. In mammals it is oxidized to carbon dioxide.
CCX915
go.drugbank.com/drugs/DB05159ExperimentalThe CCR2 receptor is thought to be of central importance to inflammatory diseases, such as multiple sclerosis (MS), Type II diabetes and atherosclerosis.
Thymectacin
go.drugbank.com/drugs/DB05116InvestigationalThymectacin was as efficacious as irinotecan, a drug recently approved for the treatment of 5-fluorouracil-resistant colon cancer. … Thymectacin, a phosphoramidate derivative of (E)-5-(2-bromovinyl)-2'-deoxyuridine, is a novel small molecule anticancer agent.
Tengonermin
go.drugbank.com/drugs/DB16689InvestigationalTengonermin, also known as NGR-hTNF, is a vascular-targeting drug. … [A233265] It is a recombinant protein and peptide-targeted agent consisting of the human Tumour Necrosis Factor-α (TNF-α) conjugated with the CNGRCG peptide.
CMC 001
go.drugbank.com/drugs/DB05353InvestigationalCMC 001 is an orally administered MRI contrast agent in development for enhancement of the liver, bile ducts and gastrointestinal tract.
ATHX-105
go.drugbank.com/drugs/DB06008InvestigationalATHX-105 is an investigational selective 5HT2c receptor agonist developed by Athersys Inc. for the treatment of Obesity.